HRS-9231

以肾功能正常受试者为对照，评价HRS-9231注射液在轻度、中度、重度以及终末期肾功能衰竭（ESRD）透析的肾功能不全受试者中的药代动力学（PK）特征、安全性和耐受性。

This is an open-label, non-randomized, parallel cohorts design, multicenter, single dose phase I study.
The primary objectives are:
To evaluate the pharmacokinetics (plasma and urine) profile of HRS-9231 following single intravenous injection (0.05 mmol/kg body weight) in patients with mild to severe renal impairment and in healthy volunteers with normal renal function used as reference.
To assess dialysability of HRS-923 following a single intravenous injection (0.05 mmol/kg body weight) in patients with end stage renal disease requiring hemodialysis.